• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Editorial Staff
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Asian Pacific Journal of Cancer Prevention
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 20 (2019)
Volume Volume 19 (2018)
Volume Volume 18 (2017)
Volume Volume 17 (2016)
Volume Volume 16 (2015)
Volume Volume 15 (2014)
Volume Volume 14 (2013)
Issue Issue 12
Issue Issue 11
Issue Issue 10
Issue Issue 9
Issue Issue 8
Issue Issue 7
Issue Issue 6
Issue Issue 5
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 13 (2012)
Volume Volume 12 (2011)
Volume Volume 11 (2010)
Volume Volume 10 (2009)
Volume Volume 9 (2008)
Volume Volume 8 (2007)
Volume Volume 7 (2006)
Volume Volume 6 (2005)
Volume Volume 5 (2004)
Volume Volume 4 (2003)
Volume Volume 3 (2002)
Volume Volume 2 (2001)
Volume Volume 1 (2000)
(2013). Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 14(12), 7111-7116.
. "Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients". Asian Pacific Journal of Cancer Prevention, 14, 12, 2013, 7111-7116.
(2013). 'Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients', Asian Pacific Journal of Cancer Prevention, 14(12), pp. 7111-7116.
Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2013; 14(12): 7111-7116.

Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients

Article 12, Volume 14, Issue 12, December 2013, Page 7111-7116  XML PDF (855.05 K)
Abstract

Introduction: Trastuzumab, an HER2-targeting agents, has shown efficacy in metastatic HER2-positivebreast cancer patients. Single-agent clinical trials have evaluated therapeutic regimens using trastuzumab formetastatic breast cancer patients. The aim of our study is to evaluate the efficacy and safety of trastuzumabin combination with chemotherapy or hormone therapy in HER2-positive metastatic breast cancer patients.
Methods: A literature research was conducted in PubMed and to identify appropriate studies from relevantreviews. Randomized controlled trials comparing chemotherapy or hormone therapy regimens in combinationwith trastuzumab were eligible. Dadta on clinical outcomes, including safety, efficacy, and patient characteristicswere collected.
Results: Seven articles describing five trials were included in our systematic review and metaanalysis.Partners of trastuzumab included in trials were anthracycline, paclitaxel, docetaxel, anastrozole andletrozole. The addition of trastuzumab to chemotherapy improved the overall survival (HR=0.79, 95%CI 0.65-0.96), while to hormone therapy did not (HR=0.85 95%CI 0.56-1.30). All trastuzumab-containing regimensincreased cardiac toxicity (RR=3.37, 95%CI 1.26-9.02) and grade Ⅲ-Ⅳ adverse events.
Conclusions: Our studysupports the addition of trastuzumab to chemotherapy which is effective and tolerated for metastatic breastcancer with HER2+ patients. Of note, more adverse events will occur followed the use of trastuzumab, especiallycardiac toxicity, with two treatment regimens.
Keywords
Trastuzumab; HER2-positive; Metastatic breast cancer; Chemotherapy; hormone therapy
Statistics
Article View: 553
PDF Download: 456
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

 



 

Journal Management System. Designed by sinaweb.